FOLH1 and cancer: PSMA inhibitors like 2-PMPA reduce uptake in both glands and tumors, compromising cancer treatment [19, 20], however, the 2-PMPA prodrug, JHU-2545, shows promise in reducing gland uptake with less impact on tumors, and clinical evaluations are ongoing [21].